Zebrafish Market

On 10 April 2025, the US Food and Drug Administration announced a plan to phase out its animal testing requirement for monoclonal antibodies and other drugs, encouraging developers to submit data from new approach methodologies instead of relying on rodents, dogs and monkeys. The policy was written around computer models, human cell lines and organoids, but it also sent drug developers looking for cheaper, faster whole-organism screens that sit before or between those methods, and the zebrafish, a small tropical fish whose transparent embryos develop organs in days, is the one most of them already knew. Douglas Insights values the zebrafish market at USD 236.4 million in 2025 and forecasts USD 585.4 million by 2035, a compound growth rate of 9.49%. The receipt is about 5,200 active zebrafish research programmes worldwide, in university labs, drug developers and contract research organisations, spending an average of USD 45,460 a year each on fish, housing, feed, services and analysis tools. Programmes grow 6.2% a year as toxicology, disease modelling and early drug screening adopt zebrafish; spend per programme grows 3.1% a year as work shifts to outsourced screening and automated imaging. The report sits within Douglas Insights coverage of life science instruments and follows the published Douglas Insights research methodology.

What does the zebrafish market cover?

The zebrafish market covers everything researchers buy to use zebrafish as a laboratory model, worth USD 236.4 million in 2025 across about 5,200 active programmes. Contract screening and toxicity services, worth USD 89.8 million in 2025, include toxicity and safety screening, efficacy testing, behavioural and cardiotoxicity assays, and the creation of genetic disease models, sold by specialist contract research organisations. Housing and husbandry systems, worth USD 63.8 million, are the recirculating water racks, tanks, filtration and water-quality controls that keep thousands of fish healthy in a facility. Fish lines, embryos and genetic models, worth USD 40.2 million, include wild-type strains, transgenic reporter lines and mutant lines made with gene editing, supplied by resource centres and commercial breeders. Feed, consumables and reagents, worth USD 26.0 million, cover live and dry diets, breeding tanks, microinjection supplies and zebrafish-specific antibodies. Imaging and behaviour instruments, worth USD 16.5 million, include automated larval imaging, heart-rate and movement tracking systems. Salaries of academic researchers, general laboratory equipment and ornamental zebrafish sold as pets are outside the boundary.

How did the FDA’s April 2025 animal testing plan affect the zebrafish market?

The FDA’s April 2025 plan lifted demand for zebrafish screening services, which Douglas Insights estimates grew about 14% in 2025 to USD 89.8 million, though the policy does not name zebrafish among its preferred methods. The FDA announcement of 10 April 2025 said animal testing would be reduced, refined or potentially replaced using computer models, cell lines and organoid testing, and that implementation would begin immediately for investigational new drug applications. The FDA reported a year later, in its year-one progress update, that it had met its first-year goals, including draft guidance on reducing non-human primate testing for monoclonal antibodies. Zebrafish sit in an unusual place in that shift. They are still animals, but larvae in the first five days of life are not protected animals under European law and cost a fraction of a rodent study, so drug developers use them as a whole-organism check on toxicity, heart effects and behaviour before committing to mammalian studies. Douglas Insights expects the policy to add about 1.5 points a year to zebrafish programme growth through 2030, most of it in outsourced toxicology. The same logic already reshaped endotoxin testing, where the FDA has moved away from horseshoe crab blood; the Bacterial Endotoxin Testing Service Market report follows that switch.

What drives zebrafish demand?

Zebrafish demand is driven by five forces, and Douglas Insights attributes 6.2 points of the 9.49% annual growth to more programmes and 3.1 points to higher spend per programme.

Cost and speed in early safety screening are the strongest force. A zebrafish larval toxicity screen can test dozens of compounds in a week using milligrams of each, against months and far larger quantities for a rodent study, and Douglas Insights estimates a typical outsourced zebrafish toxicity panel costs USD 5,000 to 15,000 per compound against USD 50,000 or more for an early rodent study. Contract screening services, worth USD 89.8 million in 2025, grow 12.4% a year, the fastest of any segment.

Gene editing has made disease models quick to build. CRISPR allows a laboratory to knock out or edit a zebrafish gene and study the effect within weeks, and about 70% of human genes have at least one zebrafish counterpart. Douglas Insights counts about 1,900 programmes using zebrafish mainly for disease modelling in 2025, spending USD 73.3 million, with rare disease, cancer and neurological models growing fastest.

Regulatory interest in reducing mammalian testing adds a push. Beyond the FDA roadmap, the FDA Modernization Act 2.0 of December 2022 removed the legal requirement for animal testing before human trials, and the OECD fish embryo toxicity test guideline gives chemical and agrochemical makers an accepted method. Douglas Insights estimates agrochemical, chemical and cosmetics safety testing at USD 26.0 million in 2025, growing 10.8% a year.

Automation raises spend per programme. Automated larval imaging, heart-rate analysis and behaviour tracking turn a manual microscope assay into a high-throughput screen, and Douglas Insights estimates imaging and behaviour instruments at USD 16.5 million in 2025, growing 9.8% a year.

Asia Pacific capacity adds a fifth push. China has built national model-organism centres and a fast-growing contract research industry, and Douglas Insights estimates Asian zebrafish programmes rose from about 1,000 in 2020 to about 1,300 in 2025, growing 8.5% a year, faster than any other region. Chinese contract research organisations offer zebrafish toxicity panels at roughly 30% to 40% below European prices, which draws screening work from Western drug developers and pushes European providers to automate. Environmental monitoring adds a smaller stream: water utilities and environmental agencies use zebrafish embryo tests to check effluent toxicity, worth about USD 9.5 million in 2025 and growing 8.0% a year.

What restraints hold back the zebrafish market?

Scientific limits and facility costs hold back the zebrafish market, trimming about 2 points a year from what screening demand alone would deliver, on Douglas Insights estimates. Zebrafish are not mammals: they have no lungs, a different immune system at early stages and absorb drugs through water, so results do not always carry over to humans, and regulators still expect mammalian data for most submissions. A new zebrafish facility costs USD 0.5 million to 3 million to build and needs trained staff and constant water-quality control, so many academic groups share central facilities rather than adding capacity. Academic budgets, which fund about 39% of zebrafish spending, USD 92.2 million in 2025, follow research grant cycles and grow only 7.4% a year. Finally, the FDA’s own plan favours human-based methods such as organoids and computer models, which will compete with zebrafish for the same screening budgets over time.

Which zebrafish segment carries the most value?

Contract research screening services are the largest zebrafish segment at 38% of 2025 value, USD 89.8 million, and also the fastest-growing zebrafish segment at 12.4% a year.

Contract research screening and toxicity services are worth USD 89.8 million in 2025. Drug developers outsource zebrafish toxicity, cardiotoxicity and efficacy screens to specialists rather than building their own fish facilities, which makes this both the biggest and the fastest segment.

Housing and husbandry systems are worth USD 63.8 million in 2025. Every facility needs recirculating racks, filtration and water-quality monitoring, and new and upgraded facilities in China and Europe give 6.8% annual growth.

Fish lines, embryos and genetic models are worth USD 40.2 million in 2025. Transgenic and gene-edited lines are made to order or supplied by resource centres, growing 9.0% a year as disease modelling spreads.

Feed, consumables and reagents are worth USD 26.0 million in 2025. Diets, breeding tanks, injection supplies and antibodies are bought continuously by every facility, growing 7.2% a year.

Imaging and behaviour instruments are worth USD 16.5 million in 2025. Automated larval imaging and movement tracking raise throughput, growing 9.8% a year.

By end user, pharmaceutical and biotechnology companies account for 46% of value, USD 108.7 million; academic and government research 39%, USD 92.2 million; agrochemical, chemical and cosmetics safety testing 11%, USD 26.0 million; and environmental and water-quality monitoring 4%, USD 9.5 million. By application, toxicology takes 34%, USD 80.4 million; disease modelling 31%, USD 73.3 million; developmental biology and genetics 23%, USD 54.4 million; and behaviour and neuroscience 12%, USD 28.4 million.

Where does the zebrafish fit between cell models and rodents?

The zebrafish fits between cell-based assays and rodent studies, and Douglas Insights estimates that about 60% of zebrafish screening spend in 2025 was used to decide which compounds go on to mammalian testing. A cell line or organoid tells a developer how one tissue responds; a zebrafish larva shows how a whole body with a beating heart, a liver, blood vessels and a nervous system responds, within three to five days and in a 96-well plate. That makes the fish useful for catching heart rhythm problems, liver injury, developmental toxicity and seizure-like behaviour early, when a program still has dozens of candidates. Rodents remain the standard for pharmacokinetics and regulatory toxicology, because their physiology is closer to ours and regulators have decades of reference data. In practice, drug developers use the three layers together: computer models and cell assays to screen thousands of compounds, zebrafish to narrow the list to a handful, and rodents or other mammals for the final safety package. The FDA’s 2025 roadmap does not change that order, but it rewards developers who can show a lower-animal path, which is why Douglas Insights expects the share of drug-developer programmes using zebrafish to rise from about 44% of the top 50 in 2025 to about 60% by 2030. The biggest remaining barrier is validation: until regulators publish specific acceptance criteria for zebrafish data in drug submissions, most fish results will support internal decisions rather than replace a regulatory study.

How are zebrafish facilities built and run?

A typical zebrafish facility houses 5,000 to 50,000 fish in 1,000 to 5,000 tanks on recirculating racks, and Douglas Insights estimates that housing, feed and consumables take about 38% of zebrafish market value, USD 89.8 million in 2025. Water is filtered, sterilised with ultraviolet light and kept at about 28 degrees Celsius, with automatic dosing of salts and constant monitoring of pH and conductivity, because poor water quality is the most common cause of lost fish and failed experiments. Fish are fed two or three times a day, often with live brine shrimp or rotifers for larvae and dry diets for adults, and many facilities now use automated feeders. Breeding produces hundreds of embryos per pair each week, which is why zebrafish suit large screens. Facilities in China and Europe are the main buyers of new racks, while North American facilities are mostly replacing systems installed in the 2000s.

Where is zebrafish research bought, and which region grows fastest?

North America buys the most zebrafish research products and services, 38% of 2025 value or USD 89.8 million, and Asia Pacific grows fastest at 11.2% a year. North America leads because the United States has the largest community of zebrafish laboratories, funded by the National Institutes of Health, and the Zebrafish International Resource Center at the University of Oregon supplies lines worldwide; growth is 8.8% a year. Europe is worth USD 73.3 million, 31% of value, with strong academic facilities in the United Kingdom, Germany, the Netherlands and Spain and a cluster of contract research specialists in Spain; European rules that treat early larvae as non-protected make zebrafish attractive for screening, and growth is 9.3% a year. Asia Pacific is worth USD 59.1 million and grows fastest because China is building large model-organism centres and contract research capacity, and Japan, South Korea and Singapore have established zebrafish research. Latin America, at USD 7.1 million, grows 8.6% a year from Brazilian and Chilean universities. The Middle East and Africa together are worth about USD 7.1 million; the Middle East is the wildcard, where new biomedical research institutes in Saudi Arabia and Qatar could lift growth above the 9.0% base case.

Who supplies the zebrafish market?

Tecniplast leads the zebrafish market through housing systems with an estimated 16% of 2025 value, and the top three suppliers hold about 31%, on Douglas Insights estimates; contract screening is more fragmented.

Tecniplast’s position rests on complete facility systems installed in major research institutes. Aquaneering and Pentair compete in North American facilities. ZeClinics and Biobide lead contract screening in Europe, InVivo Biosystems builds custom disease models in the United States, and BioReperia in Sweden and the Shanghai Model Organisms Center in China add specialist capacity. Viewpoint and Noldus sell behaviour tracking tools used in neuroscience screens. Douglas Insights expects contract research to consolidate as drug developers look for providers that can run zebrafish, cell and computer models together.

How is zebrafish research priced?

Zebrafish research prices range from about USD 5,000 per compound for a basic outsourced toxicity screen to USD 3 million for a complete facility, and the Douglas Insights average spend per programme is USD 45,460 a year in 2025. Outsourced toxicity and cardiotoxicity panels cost USD 5,000 to 15,000 per compound, and efficacy studies in a disease model USD 20,000 to 80,000. A custom gene-edited zebrafish line costs USD 8,000 to 20,000 to create. A single housing rack system costs USD 25,000 to 120,000, and a full facility USD 0.5 million to 3 million. Automated larval imaging and behaviour systems sell for USD 60,000 to 250,000. Spend per programme grows about 3.1% a year as work moves from in-house bench assays to outsourced and automated screens.

How could the zebrafish forecast change by 2035?

The zebrafish forecast ranges from about USD 435 million to USD 784 million in 2035 across Douglas Insights scenarios, around a base case of USD 585.4 million. The slower case assumes programme growth of 4.2% a year and spend growth of 2.0%, which would follow if organoids and computer models capture most of the screening budget freed by the FDA plan. The faster case assumes 8.4% and 4.0%, which would follow if regulators formally accept zebrafish data in safety packages. Published forecasts for zebrafish markets run between 13.2% and 15.4% a year from a base near USD 120 million. Douglas Insights’ 9.49% sits below that range because this study includes slower-growing housing, feed and academic spending, and because the FDA’s roadmap names human-based methods rather than fish as its main replacements.

Douglas Exclusive: zebrafish screening adoption tracker

The Douglas Insights zebrafish screening adoption tracker follows the top 50 drug developers and 40 contract research organisations, recording which use zebrafish in toxicology, disease modelling or efficacy screening and how many compounds pass through each year. It shows that about 22 of the top 50 drug developers used outsourced zebrafish screens in 2025, up from about 14 in 2022, and that the average developer screened about 180 compounds in zebrafish in 2025. The tracker also records regulatory submissions that cite zebrafish data.

Which regulations and standards shape the zebrafish market?

Animal welfare law and drug testing policy shape the zebrafish market, and Douglas Insights estimates about 70% of zebrafish screening uses larvae young enough to fall outside European animal protection rules. Directive 2010/63/EU on the protection of animals used for scientific purposes covers fish only from the stage of independent feeding, which for zebrafish is about five days after fertilisation, so screens run on younger larvae face lighter licensing. In the United States, the FDA Modernization Act 2.0 of December 2022 removed the statutory requirement for animal testing before clinical trials, and the April 2025 FDA roadmap encourages alternative methods. The OECD fish embryo acute toxicity test guideline gives chemical makers an accepted zebrafish method for environmental safety data.

What methodology sits behind the zebrafish market model?

The zebrafish market model is a bottom-up count across 28 countries: Douglas Insights multiplied about 5,200 active zebrafish research programmes by an average annual spend of USD 45,460 to reach USD 236.4 million in 2025. Programmes were counted from university and institute zebrafish facilities, drug developers and contract research organisations, checked against publication counts and resource centre distribution data. Spend per programme combines services, fish lines, housing depreciated over its working life, feed and consumables, and instruments, checked against supplier price lists. Shares for leading suppliers are Douglas Insights estimates. The Biopharmaceutical Single-Use Bioprocessing Market report covers the manufacturing side of the biologics these screens support. Full receipts are in the Douglas Insights research methodology.

Sources

1. U.S. Food and Drug Administration FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs (10 April 2025) (2025)
2. U.S. Food and Drug Administration FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development (2026)
3. U.S. Food and Drug Administration Search for FDA Guidance Documents (2026)